Immune system activation via Bacillus Calmette-Guérin (BCG-induced immune activation)

"Immune system activation via Bacillus Calmette–Guérin" does not refer to a single molecular target but rather describes the broad immunological effects triggered by administration of the live attenuated Mycobacterium bovis strain known as BCG. Upon administration, BCG is taken up by innate immune cells such as dendritic cells, macrophages, and neutrophils. This leads to maturation of antigen-presenting cells with increased expression of co-stimulatory molecules (e.g., CD80/CD86), presentation on MHC class II molecules, and subsequent priming of T helper 1 (Th1) CD4+ T cell responses as well as CD8+ cytotoxic T lymphocyte responses through cross-presentation. Additionally, BCG induces epigenetic changes in innate immune cells—termed "trained immunity"—which enhances their responsiveness to subsequent infections or challenges. Clinically, these mechanisms underlie both its use as a tuberculosis vaccine and its application in bladder cancer immunotherapy where it augments anti-tumor immunity primarily through enhancement of tumor-specific CD4+ T cell function[1][2][3]. However, this entry is not a canonical molecular target such as a receptor or enzyme; it refers instead to an entire process or pathway involving multiple cellular components. Therefore it should not be considered a standard therapeutic target for structured databases focused on discrete biomolecules. If you need information about specific receptors or pathways activated downstream from BCG exposure (such as Toll-like receptors or cytokine signaling pathways), please specify further so that more precise molecular targets can be identified.

Other names

Bacillus Calmette-Guérin immunomodulationBCG-mediated immune responseBCG vaccine-induced immunity

1. Induction of innate and adaptive immune responses through phagocytosis by dendritic cells, macrophages, and neutrophils 2. Activation of antigen-presenting cells leading to T cell priming and Th1 differentiation via IL‑12 3. Epigenetic reprogramming ("trained immunity") in monocytes/macrophages 4. Augmentation of tumor-specific T cell effector functions in cancer therapy